Evidence map›Paper›PMID 41025518›Full record

ArticleGlycobiology2025

Production and inhibition of human Heparan 6-O-Endosulfatase SULF1.

Reem Aljuhani, Julius Benicky, Aswini Panigrahi, Pritha Mukherjee, Miloslav Sanda, Shiya Zhu, Zora Nováková, Vitor H Pomin, Jian Liu, Bruce Davidson and 2 more

Abstract read
In one paragraph

Article in Glycobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Reem AljuhaniClinical and Translational Glycoscience Research Center, Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20057, United States.ORCID 0009-0000-1466-1238
Julius BenickyClinical and Translational Glycoscience Research Center, Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20057, United States.ORCID 0000-0002-1941-1622
Aswini PanigrahiClinical and Translational Glycoscience Research Center, Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20057, United States.
Pritha MukherjeeClinical and Translational Glycoscience Research Center, Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20057, United States.
Miloslav SandaClinical and Translational Glycoscience Research Center, Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20057, United States.
Shiya ZhuDepartment of Biochemistry and Molecular & Cellular Biology, 3800 Reservoir Rd NW, Georgetown University, Washington, DC 20057, United States.
Zora NovákováInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec 252 50, Czech Republic.
Vitor H PominDepartment of BioMolecular Sciences, University of Mississippi, University, Mississippi 38677, United States.ORCID 0000-0002-5015-8880
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, United States.
Bruce DavidsonDepartment of Otolaryngology-Head and Neck Surgery, MedStar Georgetown University Hospital, Washington, DC 20057, United States.
Cyril BařinkaInstitute of Biotechnology of the Czech Academy of Sciences, BIOCEV, Prumyslova 595, Vestec 252 50, Czech Republic.
Radoslav GoldmanClinical and Translational Glycoscience Research Center, Georgetown University, 3800 Reservoir Rd NW, Washington, DC 20057, United States.ORCID 0000-0003-1304-0522

Funding

O-glycoproteins in the progression of liver diseaseR01CA238455 · NCI · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2019 to 2023
$2.6M
timsTOF Pro Mass SpectrometerS10OD028623 · OD · GEORGETOWN UNIVERSITY · PI GOLDMAN, RADOSLAV · 2021 to 2021
$600k
Georgetown University Lombardi Comprehensive Cancer Center 2P30CA051008NCI NIH HHS R01 CA238455NIH HHS R01CA238455NIH HHS S10 OD028623NIH HHS S10OD028623
6 · The paper itself

Abstract

SULF1, a human extracellular heparan 6-O-endosulfatase isoform 1, plays a critical role in embryonic development and cancer progression by modulating the 6-O-sulfation of heparan sulfate proteoglycans. However, limited recombinant protein production has hindered structural and functional characterization. To address this issue, we optimized SULF1 expression in HEK293F and HEK293T cells. We achieved yields of 2.2 mg/L of culture media after Ni2+-affinity purification of greater than 80% purity, representing a substantial improvement compared to the reported expression systems. We demonstrated that co-expression of sulfatase-modifying factor 1 in this expression system is essential for enhancing SULF1 enzymatic activity, which depends on conversion of active site cysteine to Cα-formylglycine and the presence of a Ca2+ ion. We further showed that a marine fucosylated chondroitin sulfate polymer isolated from the sea cucumber Holothuria floridana inhibits SULF1 enzymatic activity with IC50 of 0.05 ± 0.006 μg/mL and 0.07 ± 0.008 μg/mL for the GlcNS6S-GlcA-GlcNS6S-IdoA2S-GlcNS6S-IdoA2S-GlcNS6S-GlcA and 4-methylumbelliferyl sulfate substrates, respectively. Kinetic analysis revealed a mixed-mode inhibition, characterized by alterations in Vmax at all inhibitor concentrations and Km at high inhibitor concentrations. Efficient SULF1 production also enabled us to develop specific monoclonal antibodies, which confirmed SULF1 expression in the stroma of head and neck squamous cell cancer tissues. Collectively, this study provides an efficient workflow for the production of active human SULF1, investigates SULF1 inhibitors, and characterizes anti-SULF1 monoclonal antibodies, which will support further studies of this enzyme in various pathophysiological conditions.

Indexed as

Enzyme InhibitorsSulfotransferasesAnimalsHEK293 CellsHumansRecombinant ProteinsEnzyme InhibitorsRecombinant ProteinsSULF1 protein, humanSulfotransferasescalcium ionenzymatic activityHeparan 6-O-endosulfatase SULF1N-glycosylationSulfatase modifying factor SUMF1

Identifiers

PMID41025518
PMCPMC12665892

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.